derivatives of 2b, have the potential to provide effective
antisense activity by inducible alkylation in the cell. Further
studies of these ICL reactions and their applications are
currently ongoing.
This work was supported by a Grant-in-Aid for Scientific
Research (B) from Japan Society for the Promotion of Science
(JSPS), CREST from Japan Science and Technology Agency.
Notes and references
1 J. M. Kean, A. Murakami, K. R. Blake, C. D. Cushman and
P. S. Miller, Biochemistry, 1988, 27, 9113–9121.
2 L. Ma, J. Teruya-Feldstein and R. A. Weinberg, Nature, 2007, 449,
682–689.
3 C. C. Esau, Methods, 2008, 44, 55–60.
4 S. Davis, S. Propp, S. M. Freier, L. E. Jones, M. J. Serra,
G. Kinberger, B. Bhat, E. E. Swayze, C. F. Bennett and C. Esau,
Nucleic Acids Res., 2009, 37, 70–77.
5 M. Higuchi, A. Kobori, A. Yamayoshi and A. Murakami, Bioorg.
Med. Chem., 2009, 17, 475–483.
6 X. H. Peng, I. S. Hong, H. Li, M. M. Seiclman and
M. M. Greenberg, J. Am. Chem. Soc., 2008, 130, 10299–10306.
7 Y. Yoshimura and K. Fujimoto, Org. Lett., 2008, 10, 3227–3230.
8 E. E. Weinert, R. Dondi, S. Colloredo-Melz, K. N. Frankenfield,
C. H. Mitchell, M. Freccero and S. E. Rokita, J. Am. Chem. Soc.,
2006, 128, 11940–11947.
Fig. 4 HPLC analysis of the ICL reactions between 11 and DNA
(12c) (50AGAAAGGAGAATAAAG30) in (A) and the adducts from
the enzymatic hydrolysate (B). The ICL reaction was performed under
the same conditions as in Fig. 2. HPLC conditions for A: ODS
column, 1.0 mL minꢂ1; solvent A 0.1 M TEAA; solvent B CH3CN,
linear gradient from 10–40% over 20 min and monitored at 254 nm.
Peak 17 was isolated and digested with snake venom phospho-
diesterase I and bacterial alkaline phosphatase in buffer (50 mM
Tris-HCl, 10 mM MgCl2). HPLC conditions for part B: ODS column,
1 mL minꢂ1; solvent A, 50 mM ammonium formate, solvent B CH3CN,
linear gradient from 5–30% over 30 min and monitored at 260 nm. Peak
18 was isolated and its structure determined as shown in (C).
9 Z. Qiu, L. Lu, X. Jian and C. He, J. Am. Chem. Soc., 2008, 130,
14398–14399.
10 K. Stevens and A. Madder, Nucleic Acids Res., 2009, 37,
1555–1565.
11 M. M. Ali, M. Oishi, F. Nagatsugi, K. Mori, Y. Nagasaki,
K. Kataoka and S. Sasaki, Angew. Chem., Int. Ed., 2006, 45,
3136–3140.
12 F. Nagatsugi, T. Kawasaki, D. Usui, M. Maeda and S. Sasaki,
J. Am. Chem. Soc., 1999, 121, 6753–6754.
13 T. Kawasaki, F. Nagatsugi, M. M. Ali, M. Maeda, K. Sugiyama,
K. Hori and S. Sasaki, J. Org. Chem., 2005, 70, 14–23.
14 F. Nagatsugi, Y. Matsuyama, M. Maeda and S. Sasaki,
Bioorg. Med. Chem. Lett., 2002, 12, 487–489.
15 F. Nagatsugi, D. Usui, T. Kawasaki, M. Maeda and S. Sasaki,
Bioorg. Med. Chem. Lett., 2001, 11, 343–345.
pathways. The structure determination of the cross-linked
product in ODNs is in progress. The experimental studies on
cross-linking reaction pathways are quite often very limited20
and future combined experimental and computational studies
of the cross-linking reaction pathways must be suggested with
the ultimate goal of identifying all the relevant transition and
product structures. A computational study of the cross-linking
reaction using 4-amino-6-oxo-2-vinylpyrimidine is indispensable
to discuss the reaction pathway.
16 T. Hirayama, M. Kamada, H. Tsurumi and M. Mimura,
Chem. Pharm. Bull., 1976, 24, 26–35.
In conclusion, we have demonstrated a highly selective and
very fast ICL reaction to thymine using the novel nucleoside
derivative 2b without photo-irradiation. New cross-linking
motifs based on 2b will be generally useful for site-directed
chemical modification of thymine within a selected target.
It is expected that the stable precursors, sulfide protected
17 M. M. Paz and P. B. Hopkins, J. Am. Chem. Soc., 1997, 119,
5999–6005.
18 M. Y. Wang, Y. B. Lao, G. Cheng, Y. L. Shi, P. W. Villalta and
S. S. Hecht, Chem. Res. Toxicol., 2007, 20, 625–633.
19 H. Borowy-Borowski and R. W. Chambers, Biochemistry, 1989,
28, 1471–1477.
20 P. M. Mitrasinovic, Bioconjugate Chem., 2005, 16, 588–597.
ꢀc
This journal is The Royal Society of Chemistry 2009
Chem. Commun., 2009, 6463–6465 | 6465